Hypofractionated Radiotherapy in Breast Cancer Patients With Prosthetic Reconstruction
Randomized Phase III Clinical Trial of Hypofractionated Radiotherapy in Breast Cancer Patients With Immediate Prosthetic Reconstruction: PROMART Trial
Barretos Cancer Hospital
120 participants
Jun 27, 2022
INTERVENTIONAL
Conditions
Summary
RATIONALE: Radiotherapy (RT) can be indicated to patients submitted to breast-conserving surgery, but, despite the benefits, adjuvant RT can cause contracture generated by tissue fibrosis in patients with immediate prosthetic reconstruction, which could cause prosthesis loss. The biological explanation of this outcome is not fully understood, but recent advances in the analysis of patient-derived blood can contribute to establishing a connection of molecular alterations related to this clinical outcome. There is not a consensus about using hypofractionated RT schemes for patients with BCS and breast reconstruction since no studies had investigated the reasons why some patients lose the prosthesis. PURPOSE: This study will evaluate G3 toxicity rate in breast cancer patients with immediate prosthetic reconstruction, submitted to hypofractionated radiotherapy, analyzing capsular contracture, leakage, infection, and bad positioning in order to demonstrate the noninferiority of Hypo-RT with the conventional RT. Additionally, the molecular profile of blood samples will be investigated in order to find biomarkers related to inflammations processes and response to treatment.
Eligibility
Inclusion Criteria8
- Women with confirmed histological diagnosis of invasive ductal carcinoma and lobular breast carcinoma;
- Radical mastectomy with immediate reconstruction with a prosthesis;
- Patients indicated for adjuvant RT;
- Any lymph node status;
- With or without adjuvant chemotherapy;
- ECOG performance status from 0-2;
- \> 18 years old;
- Informed Consent Form applied before any study-specific procedure.
Exclusion Criteria5
- Another histological diagnosis than invasive ductal carcinoma or lobular carcinoma;
- Previous history of neoplasm and/or radiotherapy and/ or quimiotherapy before this study;
- Distant metastatic disease;
- Palliative treatment;
- Patients with scleroderma / systemic lupus erythematosus.
Interventions
Hypofractionation scheme will comprise 40 Gy in 15 fractions
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05491395